Answers are grounded in this paper and cite their sources.
Patent discloses tetrahydropyrrolooxazolones as RIPK1 inhibitors, suggesting potential treatments for related diseases.
This patent discloses tetrahydropyrrolooxazolones as novel receptor-interacting protein kinase 1 (RIPK1) inhibitors as potential treatments for RIPK1-related diseases. It provides details in the synthesis of the tetrahydropyrrolooxazolones, pharmaceutical compositions, and therapeutic applications for RIPK1-related diseases.
No takes yet. Share an insight, caveat, or question.
Rong et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: